--- title: "60 DEGREES PHARMACEUTICALS INC C/WTS 12/07/2028 (TO PUR COM) | 10-K: FY2025 Revenue: USD 1.005 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/281079608.md" datetime: "2026-03-30T21:38:23.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281079608.md) - [en](https://longbridge.com/en/news/281079608.md) - [zh-HK](https://longbridge.com/zh-HK/news/281079608.md) --- # 60 DEGREES PHARMACEUTICALS INC C/WTS 12/07/2028 (TO PUR COM) | 10-K: FY2025 Revenue: USD 1.005 M Revenue: As of FY2025, the actual value is USD 1.005 M. EPS: As of FY2025, the actual value is USD -11.73. EBIT: As of FY2025, the actual value is USD -7.855 M. The company operates and manages its business as a single identifiable segment, focusing on the development and marketing of new medicines for infectious diseases . #### Revenue - **Product Revenues - net of Discounts and Rebates** increased by 65.49% to $1,005,471 in 2025 from $607,574 in 2024 . U.S. pharmaceutical distributors accounted for 92% of total net product sales in 2025 (95% in 2024), while Kodatef sales to the Australian distributor accounted for 6% (5% in 2024) . Discounts and rebates totaled $476,430 in 2025, compared to $476,218 in 2024 . - **Research Revenues** significantly increased by 447.13% to $403,624 in 2025 from $73,771 in 2024, primarily due to a new USAMMDA contract for Arakoda supply chain upgrade support ($298,868 in 2025 vs $12,994 in 2024) and $89,302 from the University of Kentucky . - **Net Revenue** was $627,400 in 2025, up from $296,580 in 2024 . #### Operational Metrics - **Cost of Revenues** increased by 103.16% to $781,695 in 2025 from $384,765 in 2024, partly due to higher product sales and $445,181 in inventory write-offs for expiring inventory in 2025 (vs $22,046 in 2024) . - **Gross Profit** was $223,776 in 2025, a 0.43% increase from $222,809 in 2024 . - **Gross Margin** decreased from 36.67% in 2024 to 22.26% in 2025 . - **Research and Development expenses** decreased by - $2,880,370 (-57.76%) to $2,106,156 in 2025 from $4,986,526 in 2024, mainly due to non-cash charges of $3,225,000 recognized in 2024 . Direct trial-related costs for the babesiosis trial were $1,496,148 in 2025, compared to $1,359,532 in 2024 . - **General and Administrative Expenses** increased by $1,254,588 (24.97%) to $6,279,823 in 2025 from $5,025,235 in 2024, driven by higher legal and professional fees, investor outreach, advertising, promotion expenses, and increased stock-based compensation costs . - **Total Operating Expenses** were $8,385,979 in 2025, a -16.24% decrease from $10,011,761 in 2024 . - **Loss from Operations** was - $7,758,579 in 2025, an improvement from - $9,715,181 in 2024 . - **Interest Expense** was - $7,805 in 2025, similar to - $7,912 in 2024 . - **Change in Fair Value of Derivative Liabilities** resulted in a gain of $266,089 in 2025, a decrease from the $1,665,966 gain in 2024 . - **Other Income, net** was $131,970 in 2025, up from $101,464 in 2024 . - **Net Loss attributed to 60 Degrees Pharmaceuticals, Inc.** improved to - $7,365,158 in 2025 from - $7,947,107 in 2024 . - **Net Loss per Common Share (Basic and Diluted)** was - $11.73 in 2025, an improvement from - $74.17 in 2024 . #### Cash Flow - **Net Cash Used in Operating Activities** increased to - $6,849,022 in 2025 from - $5,648,088 in 2024 . - **Net Cash Provided by (Used in) Investing Activities** was $254,916 in 2025, a significant change from - $1,889,114 in 2024, primarily due to maturities of short-term investments . - **Net Cash Provided by Financing Activities** was $6,437,691 in 2025, a decrease from $7,053,571 in 2024 . #### Unique Metrics - **Arakoda Sales Volume (16-ct box equivalents)** increased by 12% to 5,724 units in 2025 from 5,119 units in 2024 . - **Kodatef sales volume** in Australia showed less than 1% year-over-year growth, with 1,854 boxes sold in 2025 compared to 1,850 boxes in 2024 . - **Arakoda sales volume in Europe** by Scandinavian Biopharma increased to 353 boxes in 2025 from 147 boxes in 2024, driven by greater interest in treating babesiosis . #### Outlook / Guidance 60 Degrees Pharmaceuticals, Inc. estimates it will have sufficient funds to remain viable through September 30, 2026, assuming no additional capital raises . The company plans to fund operations through debt/advances, private placement of restricted securities, and stock issuance until profitability or a business combination is achieved . However, the lack of assurance for successfully raising additional capital or achieving profitability raises substantial doubt about its ability to continue as a going concern . ### Related Stocks - [SXTPW.US](https://longbridge.com/en/quote/SXTPW.US.md) ## Related News & Research - [POMDOCTOR LIMITED Announces Fiscal Year 2025 Financial Results | POM Stock News](https://longbridge.com/en/news/286463818.md) - [Tesla Begins Construction on New Kingston Supercharger [Ontario]](https://longbridge.com/en/news/286805373.md) - [Davis Commodities Limited Announces Fiscal Year 2025 Financial Results | DTCK Stock News](https://longbridge.com/en/news/286606124.md) - [Arm Holdings Tech Rally Takes Breather As Investors Weigh Supply Chain Risks](https://longbridge.com/en/news/286433450.md) - [Always-on fraud checks cut Suncoast's losses by a third](https://longbridge.com/en/news/286815368.md)